Study of Autologous Hair Follicle Secretome Injections to Treat Hair Loss from Androgenic Alopecia in Adults Aged 18 to 65

What this Trial Is About

Researchers are evaluating an autologous hair follicle-derived secretome as a treatment for androgenic alopecia, a common cause of hair loss affecting men and women. This trial aims to study the safety and effectiveness of injecting this secretome into the scalp compared to a saline placebo. The study will include 60 patients who have been on a stable regimen of minoxidil and 5-alpha reductase inhibitors for at least six months. Participants will receive injections of the secretome diluted with saline or placebo at baseline and on days 30, 90, 180, 270, and 365. The injections will be administered in a grid-like pattern across affected areas of the scalp, with about 20 injections per quadrant. Each vial of secretome is diluted in 2ml saline, and each quadrant receives one vial. The study is double-blind and placebo-controlled. During the trial, hair growth will be measured by density and thickness at various time points, and patient-reported outcomes will be collected. Safety will be monitored, with assessments including Target Area Hair Counts and patient satisfaction. Participants must attend all study visits and agree to maintain their hairstyle and tolerate injections. The total study duration is one year, with multiple follow-up assessments.

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)